Reply to: Comment on: A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials
1 Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts, USA.
2 Vall d'Hebron Research Institute and Department of Pediatric Hematology and Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
3 Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany.
4 BTG International Inc., Conshohocken, PA, USA.
5 Protherics Medicines Development Ltd., London, UK.
6 Unit of Pediatrics, Foundation IRCCS San Gerardo dei Tintori, Monza, Italy.
7 Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.